A Phase 2/3 interventional study of Cobolimab and Dostarlimab in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline. Active, not recruiting at 163 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by GlaxoSmithKline · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 3rd largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2020, is the only one in phase 2/3, and was the 46th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:
Nuvalent Inc. · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 8
First in 2000; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 758 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 88 across the 47 interventional studies, 1 across the 3 observational. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02817633Tesaro, Inc.A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Cobolimab · Biological: Dostarlimab · Drug: Docetaxel
Biological: Dostarlimab · Drug: Docetaxel
Drug: Docetaxel
Cobolimab will be administered.
Dostarlimab will be administered.
Docetaxel will be administered.
Overall Survival (OS) (Arm A Versus Arm C)
OS is defined as the time from the date of randomization to the date of death due to any cause.
Time frame: Up to approximately 234 weeks
Overall Survival (OS) (Arm B Versus Arm C)
OS is defined as the time from the date of randomization to the date of death due to any cause.
Time frame: Up to approximately 234 weeks
Overall Survival (OS) (Arm A Versus Arm B)
OS is defined as the time from the date of randomization to the date of death due to any cause.
Time frame: Up to approximately 234 weeks
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or confirmed partial response (PR) as the best overall response based on Investigator assessment, evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 . PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
Time frame: Up to approximately 234 weeks
Progression Free Survival (PFS)
PFS is defined as the length of time from randomization to the earliest date of assessment of disease progression based on RECIST v1.1 by Investigator assessment or death by any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start. In addition, the sum has an absolute increase from nadir of 5 mm.)
Time frame: Up to approximately 234 weeks
Duration of Response (DOR)
DOR is defined as the time from first documented response (CR/PR) until the time of first documentation of disease progression based on RECIST version 1.1 by Investigator assessment or death, whichever occurs first. PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
Time frame: Up to approximately 234 weeks
Time to Deterioration (TTD) in Lung Cancer
TTD in lung cancer is defined as time from randomization to meaningful deterioration on a composite endpoint of dyspnea, chest pain, and cough, from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 13 item Lung Cancer Module (EORTC-QLQ-LC13).
Time frame: Up to approximately 234 weeks
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These include five functional scales (physical functioning \[PF\], role functioning \[RF\], emotional functioning \[EF\] cognitive functioning \[CF\] and social functioning \[SF\]), three symptom scales (fatigue, nausea/vomiting \[N/V\] and pain), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (dyspnea, insomnia, appetite loss \[AL\], constipation, diarrhea and financial difficulties \[FD\]). Response options are 1 (Not at all) to 4 (Very much). Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline [Day(D) -1],D1 on Cycle(C)(s) 2,3,4,5,6,9,12,15,18,22,26,30,34,38,42,46,50,54, 58,62,66, End of treatment (EoT- up to approximately(~) 216 weeks), Safety follow up (SFU) at D30 after EOT (~ 220 weeks) & at D90 after EOT (~ 229 weeks)
Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 13 Item Lung Cancer Module (EORTC-QLQ-LC13) Assessment
The QLQ-LC13 questionnaire comprises 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea and site-specific pain which includes pain in chest, pain in arm or shoulder and pain in other parts), and treatment-related side effects (sore mouth \[SM\], dysphagia, peripheral neuropathy \[PN\] and alopecia). Response options are 1 (Not at all) to 4 (Very much). Scores were averaged and transformed to 0 to 100. Higher scores represent increasing symptom levels. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (D -1),D1 on Cycle(C)(s) 2,3,4,5,6,9,12,15,18,22,26,30,34,38,42,46,50,54, 58,62,66, End of treatment (EoT- up to approximately(~) 216 weeks), Safety follow up (SFU) at D30 after EOT (~ 220 weeks) & at D90 after EOT (~ 229 weeks)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings
ECGs were recorded after the participants were in a supine or semi-recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes. ECG findings are summarized as clinically significant change from baseline worst case hierarchy: Yes \> No \> Not Applicable (NA).
Time frame: Baseline (Day-1) up to Cycle 1 Day 1
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs (SAEs) and Immune-mediate AEs (imAEs)
A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to 329 weeks
Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
Time frame: Up to 329 weeks
Number of Participants Using Concomitant Medications
Number of participants using concomitant medications will be presented.
Time frame: Up to 329 weeks
Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Blood samples will be collected for the analysis of hematology parameters.
Time frame: Up to 329 weeks
Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples will be collected for the analysis of Clinical Chemistry parameters.
Time frame: Up to 329 weeks
Number of Participants With Worst Case Thyroid Function Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples will be collected for the analysis of thyroid function
Time frame: Up to 329 weeks
Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Post-Baseline Relative to Baseline
Urine samples will be collected to analyze urine specific gravity.
Time frame: Up to 329 weeks
Number of Participants With Worst Case Vital Signs Results Relative to Normal Range Post-Baseline Relative to Baseline
Vital signs will be assessed
Time frame: Up to 329 weeks
Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Vital Signs
Vital signs will be assessed and presented
Time frame: Baseline (Day -1) and Up to 281 weeks
Number of Participants With Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status
Performance status will be assessed using the ECOG performance status scale.
Time frame: Up to 329 weeks
Number of Participants With Abnormal Physical Examinations
Number of participants with abnormal physical examinations will be presented
Time frame: Up to approximately 234 weeks
| Milestone | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| Started | 305 | 301 | 152 |
| Intent-to-treat (itt) population | 305 | 301 | 152 |
| Safety (saf) population | 302 | 295 | 144 |
| Completed | 227 | 236 | 116 |
| Not completed | 78 | 65 | 36 |
| Withdrew: Lost to follow-up | 3 | 2 | 1 |
| Withdrew: Withdrawal by subject | 7 | 16 | 13 |
| Withdrew: Ongoing at the time of analysis | 68 | 47 | 22 |
OS is defined as the time from the date of randomization to the date of death due to any cause.
| Months | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Docetaxel (Arm C) |
|---|---|---|
| Overall Survival (OS) (Arm A Versus Arm C) | 11.9 (10.6 to 14.2) | 11.3 (9.5 to 13.9) |
OS is defined as the time from the date of randomization to the date of death due to any cause.
| Months | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|
| Overall Survival (OS) (Arm B Versus Arm C) | 11.8 (10.3 to 12.9) | 11.3 (9.5 to 13.9) |
OS is defined as the time from the date of randomization to the date of death due to any cause.
| Months | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) |
|---|---|---|
| Overall Survival (OS) (Arm A Versus Arm B) | 11.9 (10.6 to 14.2) | 11.8 (10.3 to 12.9) |
ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or confirmed partial response (PR) as the best overall response based on Investigator assessment, evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 . PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).
| Percentage of participants | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| Overall Response Rate (ORR) | 18.7 (14.5 to 23.5) | 18.3 (14.1 to 23.1) | 14.5 (9.3 to 21.1) |
PFS is defined as the length of time from randomization to the earliest date of assessment of disease progression based on RECIST v1.1 by Investigator assessment or death by any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start. In addition, the sum has an absolute increase from nadir of 5 mm.)
| Months | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| Progression Free Survival (PFS) | 4.4 (4.2 to 5.5) | 4.2 (4.0 to 5.4) | 4.1 (2.9 to 4.8) |
DOR is defined as the time from first documented response (CR/PR) until the time of first documentation of disease progression based on RECIST version 1.1 by Investigator assessment or death, whichever occurs first. PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
| Months | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| Duration of Response (DOR) | 8.3 (6.2 to 9.9) | 7.1 (6.3 to 9.4) | 8.8 (5.1 to 11.0) |
TTD in lung cancer is defined as time from randomization to meaningful deterioration on a composite endpoint of dyspnea, chest pain, and cough, from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 13 item Lung Cancer Module (EORTC-QLQ-LC13).
| Months | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| Time to Deterioration (TTD) in Lung Cancer | 1.4 (1.2 to 1.5) | 1.4 (1.0 to 1.4) | 1.1 (0.8 to 1.4) |
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These include five functional scales (physical functioning \[PF\], role functioning \[RF\], emotional functioning \[EF\] cognitive functioning \[CF\] and social functioning \[SF\]), three symptom scales (fatigue, nausea/vomiting \[N/V\] and pain), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (dyspnea, insomnia, appetite loss \[AL\], constipation, diarrhea and financial difficulties \[FD\]). Response options are 1 (Not at all) to 4 (Very much). Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Scores on Scale | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| GHS/QoL, CFB to C2D1 | 1.0 ± 17.62 | -0.3 ± 20.06 | -0.3 ± 16.42 |
| GHS/QoL, CFB to C3D1 | 0.3 ± 20.32 | 0.5 ± 19.75 | -2.8 ± 16.98 |
| GHS/QoL, CFB to C4D1 | -0.4 ± 19.43 | -0.7 ± 21.06 | -4.7 ± 21.56 |
| GHS/QoL, CFB to C5D1 | -1.5 ± 19.26 | -0.5 ± 20.53 | 0.2 ± 19.07 |
| GHS/QoL, CFB to C6D1 | -1.3 ± 20.79 | -1.5 ± 20.31 | -8.5 ± 21.19 |
| GHS/QoL, CFB to C9D1 | -1.2 ± 18.16 | 0.4 ± 19.97 | -10.4 ± 19.28 |
| GHS/QoL, CFB to C12D1 | -4.1 ± 18.94 | -1.0 ± 20.97 | -9.8 ± 24.95 |
| GHS/QoL, CFB to C15D1 | -0.9 ± 12.18 | 0 ± 18.84 | -15.0 ± 17.08 |
| GHS/QoL, CFB to C18D1 | -2.4 ± 13.60 | -2.6 ± 17.27 | -8.3 ± 14.43 |
| GHS/QoL, CFB to C22D1 | -1.8 ± 17.24 | -5.0 ± 15.15 | 0 ± NA |
| GHS/QoL, CFB to C26D1 | -1.3 ± 15.71 | -8.9 ± 16.51 | — |
| GHS/QoL, CFB to C30D1 | 1.0 ± 15.41 | 4.5 ± 18.20 | 0 ± NA |
| GHS/QoL, CFB to C34D1 | -2.3 ± 11.00 | 4.8 ± 16.57 | 0 ± NA |
| GHS/QoL, CFB to C38D1 | -9.0 ± 18.47 | -13.9 ± 38.25 | — |
| GHS/QoL, CFB to C42D1 | 1.0 ± 19.13 | -2.1 ± 10.49 | 0 ± NA |
| GHS/QoL, CFB to C46D1 | 0 ± 22.82 | -4.2 ± 5.89 | 0 ± NA |
| GHS/QoL, CFB to C50D1 | -1.7 ± 26.61 | 8.3 ± NA | — |
| GHS/QoL, CFB to C54D1 | 1.4 ± 14.35 | -16.7 ± 11.79 | — |
| GHS/QoL, CFB to C58D1 | 12.5 ± 5.89 | -8.3 ± NA | — |
| GHS/QoL, CFB to C62D1 | -4.2 ± 5.89 | -8.3 ± NA | — |
| GHS/QoL, CFB to C66D1 | — | 8.3 ± NA | — |
| GHS/QoL, CFB to EoT (~216 weeks) | -10.7 ± 24.09 | -9.3 ± 20.16 | -11.6 ± 21.11 |
| GHS/QoL, CFB to SFU D30 (~220 weeks) | -9.4 ± 16.80 | -6.8 ± 15.07 | -7.5 ± 21.72 |
| GHS/QoL, CFB to SFU D90 (~229 weeks) | -7.7 ± 21.30 | -13.6 ± 21.45 | -2.6 ± 15.73 |
| PF, CFB to C2D1 | -1.8 ± 14.58 | -0.9 ± 15.44 | -2.5 ± 15.23 |
| PF, CFB to C3D1 | -0.1 ± 14.17 | -0.9 ± 15.74 | -3.2 ± 17.61 |
| PF, CFB to C4D1 | -1.7 ± 16.61 | -3.9 ± 16.30 | -4.1 ± 17.48 |
| PF, CFB to C5D1 | -5.3 ± 18.13 | -3.4 ± 18.83 | -5.0 ± 16.00 |
| PF, CFB to C6D1 | -3.0 ± 19.62 | -3.8 ± 17.61 | -6.2 ± 15.89 |
| PF, CFB to C9D1 | -2.4 ± 17.48 | -3.3 ± 18.67 | -9.0 ± 15.56 |
| PF, CFB to C12D1 | -4.8 ± 17.10 | -2.1 ± 15.00 | -17.3 ± 19.87 |
| PF, CFB to C15D1 | -2.8 ± 16.19 | -2.6 ± 20.35 | -16.7 ± 20.47 |
| PF, CFB to C18D1 | -0.6 ± 13.94 | -3.1 ± 14.51 | -13.3 ± 18.05 |
| PF, CFB to C22D1 | -4.2 ± 18.84 | -2.4 ± 17.88 | -16.7 ± 4.71 |
| PF, CFB to C26D1 | -3.3 ± 25.07 | -0.8 ± 15.61 | 6.7 ± NA |
| PF, CFB to C30D1 | -0.5 ± 23.47 | -2.4 ± 16.04 | -6.7 ± NA |
| PF, CFB to C34D1 | 2.8 ± 16.07 | 1.0 ± 11.17 | 6.7 ± NA |
| PF, CFB to C38D1 | 3.6 ± 21.88 | -2.2 ± 8.07 | — |
| PF, CFB to C42D1 | 12.5 ± 16.50 | 0 ± 9.43 | 13.3 ± NA |
| PF, CFB to C46D1 | 9.3 ± 14.61 | 3.3 ± 4.71 | 13.3 ± NA |
| PF, CFB to C50D1 | 9.3 ± 17.38 | 0 ± NA | — |
| PF, CFB to C54D1 | -1.1 ± 14.86 | 3.3 ± 4.71 | — |
| PF, CFB to C58D1 | 10.0 ± 23.57 | 13.3 ± NA | — |
| PF, CFB to C62D1 | -10.0 ± 4.71 | 13.3 ± NA | — |
| PF, CFB to C66D1 | — | -6.7 ± NA | — |
| PF, CFB to EOT (~216 weeks) | -13.5 ± 21.17 | -14.4 ± 24.15 | -14.0 ± 24.89 |
| PF, CFB to SFU D30 (~220 weeks) | -9.1 ± 19.62 | -8.2 ± 17.87 | -6.7 ± 23.09 |
| PF, CFB to SFU D90 (~229 weeks) | -5.2 ± 24.42 | -15.9 ± 22.72 | -1.7 ± 10.75 |
| RF, CFB to C2D1 | -0.3 ± 25.09 | -6.3 ± 22.77 | -4.6 ± 23.28 |
| RF, CFB to C3D1 | 0 ± 26.98 | -4.0 ± 28.22 | -5.9 ± 28.58 |
| RF, CFB to C4D1 | -4.8 ± 26.55 | -7.4 ± 25.40 | -7.4 ± 25.90 |
| RF, CFB to C5D1 | -5.2 ± 28.81 | -7.4 ± 26.83 | -3.5 ± 23.72 |
| RF, CFB to C6D1 | -2.9 ± 28.62 | -5.8 ± 24.98 | -6.7 ± 22.69 |
| RF, CFB to C9D1 | -3.1 ± 29.22 | -7.1 ± 26.77 | -5.2 ± 21.41 |
| RF, CFB to C12D1 | -2.2 ± 31.40 | -5.9 ± 23.52 | -11.8 ± 29.32 |
| RF, CFB to C15D1 | -3.2 ± 25.64 | -7.3 ± 23.82 | -12.5 ± 24.80 |
| RF, CFB to C18D1 | -0.4 ± 23.14 | -7.8 ± 19.93 | -4.2 ± 8.33 |
| RF, CFB to C22D1 | -5.3 ± 28.73 | -6.8 ± 24.48 | -8.3 ± 11.79 |
| RF, CFB to C26D1 | -1.0 ± 32.29 | -8.8 ± 19.65 | 0 ± NA |
| RF, CFB to C30D1 | 0.6 ± 28.86 | -15.5 ± 26.53 | -16.7 ± NA |
| RF, CFB to C34D1 | 4.4 ± 20.67 | -2.4 ± 17.82 | 0 ± NA |
| RF, CFB to C38D1 | -1.3 ± 30.02 | -2.8 ± 35.62 | — |
| RF, CFB to C42D1 | 8.3 ± 25.20 | -12.5 ± 25.00 | 0 ± NA |
| RF, CFB to C46D1 | 6.7 ± 19.00 | -16.7 ± 23.57 | 0 ± NA |
| RF, CFB to C50D1 | 13.3 ± 18.26 | 0 ± NA | — |
| RF, CFB to C54D1 | 5.6 ± 20.18 | 0 ± 0 | — |
| RF, CFB to C58D1 | 0 ± 0 | 0 ± NA | — |
| RF, CFB to C62D1 | 0 ± 23.57 | 0 ± NA | — |
| RF, CFB to C66D1 | — | -33.3 ± NA | — |
| RF, CFB to EOT (~216 weeks) | -16.3 ± 31.44 | -17.9 ± 28.81 | -14.7 ± 29.23 |
| RF, CFB to SFU D30 (~220 weeks) | -7.7 ± 34.80 | -13.7 ± 15.71 | -14.6 ± 25.21 |
| RF, CFB to SFU D90(~229 weeks) | -2.4 ± 37.47 | -18.8 ± 27.20 | -11.5 ± 24.88 |
| EF, CFB to C2D1 | 3.7 ± 18.64 | 2.5 ± 17.74 | -0.9 ± 17.35 |
| EF, CFB to C3D1 | 3.9 ± 17.82 | 1.5 ± 19.48 | -2.3 ± 18.11 |
| EF, CFB to C4D1 | 3.6 ± 20.25 | -0.7 ± 19.13 | -0.3 ± 20.43 |
| EF, CFB to C5D1 | 3.5 ± 20.33 | -0.3 ± 20.70 | 1.6 ± 19.06 |
| EF, CFB to C6D1 | 3.6 ± 20.67 | 2.2 ± 21.96 | 1.9 ± 17.43 |
| EF, CFB to C9D1 | 3.7 ± 20.46 | -1.6 ± 19.86 | -5.5 ± 20.32 |
| EF, CFB to C12D1 | 0.1 ± 20.39 | 1.0 ± 16.53 | -3.4 ± 23.76 |
| EF, CFB to C15D1 | 1.4 ± 22.03 | 2.1 ± 20.83 | -3.1 ± 19.38 |
| EF, CFB to C18D1 | 1.7 ± 20.13 | 0.6 ± 16.66 | -6.3 ± 12.50 |
| EF, CFB to C22D1 | -0.4 ± 19.72 | 0.8 ± 18.17 | 0 ± 0 |
| EF, CFB to C26D1 | 1.2 ± 15.91 | 0.5 ± 18.97 | 0 ± NA |
| EF, CFB to C30D1 | 3.2 ± 18.57 | -1.8 ± 11.41 | 0 ± NA |
| EF, CFB to C34D1 | 5.7 ± 19.26 | -7.1 ± 20.65 | 0 ± NA |
| EF, CFB to C38D1 | -0.6 ± 16.12 | -2.8 ± 22.77 | — |
| EF, CFB to C42D1 | 6.3 ± 8.63 | 0 ± 11.79 | 0 ± NA |
| EF, CFB to C46D1 | 1.7 ± 10.87 | 12.5 ± 17.68 | -33.3 ± NA |
| EF, CFB to C50D1 | 5.0 ± 19.18 | 0 ± NA | — |
| EF, CFB to C54D1 | 15.3 ± 24.39 | 8.3 ± 23.57 | — |
| EF, CFB to C58D1 | 25.0 ± 23.57 | 0 ± NA | — |
| EF, CFB to C62D1 | 37.5 ± 41.25 | 0 ± NA | — |
| EF, CFB to C66D1 | — | -16.7 ± NA | — |
| EF, CFB to EOT (~216 weeks) | -5.3 ± 22.15 | -7.4 ± 21.20 | -7.7 ± 26.44 |
| EF, CFB to SFU D30(~220 weeks) | -2.6 ± 17.54 | -3.4 ± 14.90 | -2.1 ± 21.74 |
| EF, CFB to SFU D90(~229 weeks) | -6.0 ± 22.03 | -8.3 ± 18.12 | 1.6 ± 16.45 |
| CF, CFB to C2D1 | 0.3 ± 16.00 | -0.8 ± 18.02 | -2.1 ± 14.74 |
| CF, CFB to C3D1 | 0 ± 14.23 | -1.4 ± 16.33 | -3.9 ± 18.03 |
| CF, CFB to C4D1 | 0.1 ± 16.84 | -2.0 ± 18.05 | 0.2 ± 12.49 |
| CF, CFB to C5D1 | 0.1 ± 19.32 | -3.1 ± 16.96 | -0.6 ± 17.81 |
| CF, CFB to C6D1 | 1.6 ± 16.42 | -2.8 ± 18.35 | -0.6 ± 17.14 |
| CF, CFB to C9D1 | 2.1 ± 16.94 | -5.9 ± 19.19 | -2.3 ± 20.28 |
| CF, CFB to C12D1 | 0.9 ± 19.16 | -4.3 ± 19.39 | -2.0 ± 11.61 |
| CF, CFB to C15D1 | 1.7 ± 13.50 | -4.3 ± 22.85 | -4.2 ± 11.79 |
| CF, CFB to C18D1 | 1.6 ± 15.78 | -1.7 ± 19.74 | -4.2 ± 8.33 |
| CF, CFB to C22D1 | 3.7 ± 16.03 | -4.5 ± 17.95 | 0 ± 0 |
| CF, CFB to C26D1 | 2.0 ± 15.22 | -2.9 ± 19.75 | 0 ± NA |
| CF, CFB to C30D1 | -1.3 ± 17.59 | -9.5 ± 22.37 | 0 ± NA |
| CF, CFB to C34D1 | 1.8 ± 14.59 | -7.1 ± 16.27 | 0 ± NA |
| CF, CFB to C38D1 | -2.6 ± 20.24 | -2.8 ± 19.48 | — |
| CF, CFB to C42D1 | 2.1 ± 13.91 | -16.7 ± 13.61 | 0 ± NA |
| CF, CFB to C46D1 | 3.3 ± 13.94 | 0 ± 0 | 0 ± NA |
| CF, CFB to C50D1 | -6.7 ± 19.00 | 0 ± NA | — |
| CF, CFB to C54D1 | 2.8 ± 12.55 | 0 ± 23.57 | — |
| CF, CFB to C58D1 | 16.7 ± 23.57 | 0 ± NA | — |
| CF, CFB to C62D1 | 0 ± 0 | 0 ± NA | — |
| CF, CFB to C66D1 | — | -33.3 ± NA | — |
| CF, CFB to EOT (~216 weeks) | -6.2 ± 21.47 | -8.0 ± 20.26 | -7.7 ± 21.97 |
| CF, CFB to SFU D30(~220 weeks) | -2.6 ± 24.34 | -6.0 ± 17.31 | -2.8 ± 22.34 |
| CF, CFB to SFU D90(~229 weeks) | -6.0 ± 33.08 | -8.7 ± 22.96 | 1.0 ± 17.71 |
| SF, CFB to C2D1 | -0.3 ± 23.31 | 0.4 ± 24.37 | -4.9 ± 22.16 |
| SF, CFB to C3D1 | -0.4 ± 23.30 | 0.7 ± 24.87 | -6.7 ± 22.58 |
| SF, CFB to C4D1 | -2.8 ± 23.01 | -3.7 ± 25.81 | -4.7 ± 23.17 |
| SF, CFB to C5D1 | -3.6 ± 24.75 | -2.2 ± 25.39 | -4.7 ± 24.35 |
| SF, CFB to C6D1 | -1.6 ± 24.23 | -0.4 ± 23.51 | -3.5 ± 20.96 |
| SF, CFB to C9D1 | 1.5 ± 22.74 | -7.3 ± 28.22 | -10.9 ± 20.55 |
| SF, CFB to C12D1 | -2.0 ± 24.35 | -3.4 ± 24.53 | -3.9 ± 20.01 |
| SF, CFB to C15D1 | 0.9 ± 22.82 | 0.4 ± 18.13 | -10.4 ± 25.10 |
| SF, CFB to C18D1 | -0.4 ± 18.72 | -3.9 ± 22.61 | 4.2 ± 8.33 |
| SF, CFB to C22D1 | -2.0 ± 20.14 | -0.8 ± 21.50 | 8.3 ± 11.79 |
| SF, CFB to C26D1 | -7.8 ± 21.41 | -8.8 ± 22.14 | 0 ± NA |
| SF, CFB to C30D1 | -0.6 ± 20.27 | -9.5 ± 21.40 | 0 ± NA |
| SF, CFB to C34D1 | -1.8 ± 19.95 | -7.1 ± 21.21 | 0 ± NA |
| SF, CFB to C38D1 | -1.3 ± 28.43 | -13.9 ± 19.48 | — |
| SF, CFB to C42D1 | 4.2 ± 23.15 | -4.2 ± 43.83 | 0 ± NA |
| SF, CFB to C46D1 | 6.7 ± 19.00 | -8.3 ± 11.79 | 0 ± NA |
| SF, CFB to C50D1 | 10.0 ± 22.36 | -16.7 ± NA | — |
| SF, CFB to C54D1 | 2.8 ± 22.15 | 0 ± 23.57 | — |
| SF, CFB to C58D1 | -8.3 ± 11.79 | 16.7 ± NA | — |
| SF, CFB to C62D1 | 0 ± 0 | 16.7 ± NA | — |
| SF, CFB to C66D1 | — | -16.7 ± NA | — |
| SF, CFB to EOT (~216 weeks) | -10.8 ± 28.47 | -9.3 ± 28.76 | -12.2 ± 24.72 |
| SF, CFB to SFU D30(~220 weeks) | -7.3 ± 25.88 | -11.5 ± 23.31 | -6.9 ± 28.20 |
| SF, CFB to SFU D90(~229 weeks) | -15.5 ± 32.33 | -12.3 ± 30.66 | -2.1 ± 17.08 |
| Fatigue, CFB to C2D1 | 2.8 ± 20.65 | 2.6 ± 21.56 | 4.8 ± 17.83 |
| Fatigue, CFB to C3D1 | 1.4 ± 21.72 | 1.5 ± 22.84 | 6.3 ± 21.22 |
| Fatigue, CFB to C4D1 | 2.5 ± 24.58 | 2.5 ± 23.21 | 6.9 ± 24.99 |
| Fatigue, CFB to C5D1 | 3.8 ± 22.81 | 4.3 ± 24.72 | 3.5 ± 23.30 |
| Fatigue, CFB to C6D1 | 2.7 ± 23.95 | 4.4 ± 24.78 | 4.7 ± 22.04 |
| Fatigue, CFB to C9D1 | 3.6 ± 22.10 | 7.5 ± 23.09 | 9.6 ± 22.76 |
| Fatigue, CFB to C12D1 | 6.2 ± 25.33 | 1.9 ± 20.13 | 14.4 ± 28.26 |
| Fatigue, CFB to C15D1 | 1.1 ± 21.90 | 0.6 ± 21.32 | 12.5 ± 29.36 |
| Fatigue, CFB to C18D1 | -0.3 ± 22.29 | 3.0 ± 19.78 | 2.8 ± 10.64 |
| Fatigue, CFB to C22D1 | 3.8 ± 21.46 | -1.5 ± 14.26 | 11.1 ± 15.71 |
| Fatigue, CFB to C26D1 | -2.0 ± 22.63 | 2.0 ± 20.87 | 0 ± NA |
| Fatigue, CFB to C30D1 | 2.1 ± 23.52 | -0.8 ± 20.19 | -11.1 ± NA |
| Fatigue, CFB to C34D1 | -4.7 ± 17.10 | 1.6 ± 23.51 | -11.1 ± NA |
| Fatigue, CFB to C38D1 | -0.9 ± 28.13 | 0 ± 7.03 | — |
| Fatigue, CFB to C42D1 | -11.1 ± 15.71 | 11.1 ± 20.29 | -11.1 ± NA |
| Fatigue, CFB to C46D1 | -8.9 ± 9.30 | 5.6 ± 23.57 | 0 ± NA |
| Fatigue, CFB to C50D1 | -13.3 ± 12.17 | -11.1 ± NA | — |
| Fatigue, CFB to C54D1 | -11.1 ± 15.71 | -11.1 ± 31.43 | — |
| Fatigue, CFB to C58D1 | 0 ± 0 | 0 ± NA | — |
| Fatigue, CFB to C62D1 | -5.6 ± 7.86 | 11.1 ± NA | — |
| Fatigue, CFB to C66D1 | — | 22.2 ± NA | — |
| Fatigue, CFB to EOT (~216 weeks) | 13.9 ± 26.45 | 12.4 ± 23.75 | 12.6 ± 28.62 |
| Fatigue, CFB to SFU D30(~220 weeks) | 11.5 ± 23.65 | 10.0 ± 17.25 | 8.8 ± 23.85 |
| Fatigue, CFB to SFUP D90(~229 weeks) | 6.3 ± 28.81 | 15.5 ± 20.03 | 1.4 ± 21.03 |
| N/V, CFB to C2D1 | 1.4 ± 14.61 | 1.2 ± 18.07 | 0.3 ± 15.33 |
| N/V, CFB to C3D1 | 1.0 ± 15.49 | 1.5 ± 16.46 | 2.7 ± 15.13 |
| N/V, CFB to C4D1 | -0.5 ± 13.00 | 0.9 ± 16.22 | 1.1 ± 14.16 |
| N/V, CFB to C5D1 | 1.6 ± 15.58 | 1.9 ± 16.35 | 0.9 ± 13.88 |
| N/V, CFB to C6D1 | 0 ± 13.04 | 1.0 ± 13.42 | -2.2 ± 10.96 |
| N/V, CFB to C9D1 | -0.5 ± 13.63 | 3.3 ± 17.40 | 0.6 ± 10.43 |
| N/V, CFB to C12D1 | 1.8 ± 14.90 | 0.3 ± 10.94 | 5.9 ± 11.70 |
| N/V, CFB to C15D1 | -0.6 ± 13.60 | -0.9 ± 10.78 | 0 ± 0 |
| N/V, CFB to C18D1 | 0.4 ± 15.21 | 0 ± 11.58 | 0 ± 0 |
| N/V, CFB to C22D1 | -0.8 ± 16.65 | -0.8 ± 10.88 | 0 ± 0 |
| N/V, CFB to C26D1 | -3.4 ± 17.30 | 2.0 ± 13.02 | 0 ± NA |
| N/V, CFB to C30D1 | -3.8 ± 18.44 | 2.4 ± 14.41 | 0 ± NA |
| N/V, CFB to C34D1 | -1.8 ± 13.49 | 0 ± 19.25 | 0 ± NA |
| N/V, CFB to C38D1 | -1.3 ± 15.90 | -2.8 ± 22.15 | — |
| N/V, CFB to C42D1 | -4.2 ± 21.36 | 4.2 ± 20.97 | 0 ± NA |
| N/V, CFB to C46D1 | -10.0 ± 22.36 | 0 ± 0 | 0 ± NA |
| N/V, CFB to C50D1 | -6.7 ± 25.28 | 0 ± NA | — |
| N/V, CFB to C54D1 | -8.3 ± 20.41 | 0 ± 0 | — |
| N/V, CFB to C58D1 | 0 ± 23.57 | 0 ± NA | — |
| N/V, CFB to C62D1 | 25.0 ± 35.36 | 0 ± NA | — |
| N/V, CFB to C66D1 | — | 16.7 ± NA | — |
| N/V, CFB to EOT (~216 weeks) | 4.8 ± 17.24 | 3.1 ± 19.79 | 5.0 ± 16.67 |
| N/V, CFB to SFU D30(~220 weeks) | 4.3 ± 14.67 | -1.3 ± 12.32 | 0.7 ± 14.31 |
| N/V, CFB to SFUP D90(~229 weeks) | -2.4 ± 11.05 | 2.9 ± 19.24 | -1.0 ± 15.48 |
| Pain, CFB to C2D1 | -3.5 ± 23.49 | -3.9 ± 25.66 | 3.0 ± 24.11 |
| Pain, CFB to C3D1 | -6.4 ± 23.63 | -2.7 ± 27.45 | 3.5 ± 25.62 |
| Pain, CFB to C4D1 | -2.9 ± 27.29 | -3.5 ± 26.49 | 1.8 ± 23.82 |
| Pain, CFB to C5D1 | -1.0 ± 25.49 | -2.5 ± 25.27 | -1.5 ± 17.90 |
| Pain, CFB to C6D1 | -3.5 ± 26.53 | -1.8 ± 24.23 | -0.3 ± 18.52 |
| Pain, CFB to C9D1 | 0.7 ± 23.20 | -3.7 ± 27.74 | 6.3 ± 19.63 |
| Pain, CFB to C12D1 | 5.3 ± 24.84 | 2.5 ± 26.95 | 12.7 ± 29.77 |
| Pain, CFB to C15D1 | 1.1 ± 19.96 | 0.9 ± 27.02 | 8.3 ± 25.20 |
| Pain, CFB to C18D1 | 4.3 ± 18.58 | 3.9 ± 27.22 | 8.3 ± 9.62 |
| Pain, CFB to C22D1 | 3.3 ± 17.17 | -4.5 ± 25.29 | 16.7 ± 23.57 |
| Pain, CFB to C26D1 | 0.5 ± 21.90 | -1.0 ± 19.07 | 0 ± NA |
| Pain, CFB to C30D1 | 5.8 ± 19.40 | -8.3 ± 25.94 | 16.7 ± NA |
| Pain, CFB to C34D1 | 2.6 ± 17.80 | 0 ± 19.25 | 0 ± NA |
| Pain, CFB to C38D1 | 9.0 ± 17.50 | -5.6 ± 25.09 | — |
| Pain, CFB to C42D1 | 6.3 ± 17.68 | 0 ± 13.61 | 0 ± NA |
| Pain, CFB to C46D1 | 10.0 ± 19.00 | -8.3 ± 11.79 | 16.7 ± NA |
| Pain, CFB to C50D1 | 13.3 ± 13.94 | -16.7 ± NA | — |
| Pain, CFB to C54D1 | 5.6 ± 13.61 | -8.3 ± 11.79 | — |
| Pain, CFB to C58D1 | 16.7 ± 0 | -33.3 ± NA | — |
| Pain, CFB to C62D1 | 16.7 ± 23.57 | -16.7 ± NA | — |
| Pain, CFB to C66D1 | — | 0 ± NA | — |
| Pain, CFB to EOT (~216 weeks) | 9.4 ± 30.37 | 10.9 ± 29.98 | 10.4 ± 30.96 |
| Pain, CFB to SFU D30(~220 weeks) | 9.8 ± 23.17 | 6.0 ± 20.41 | 6.3 ± 29.00 |
| Pain, CFB to SFU D90(~229 weeks) | 4.8 ± 31.64 | 5.1 ± 32.35 | 2.1 ± 20.07 |
| Dyspnea, CFB to C2D1 | -1.7 ± 23.96 | -1.1 ± 26.64 | 1.9 ± 24.17 |
| Dyspnea, CFB to C3D1 | -3.0 ± 26.78 | -0.5 ± 27.25 | 3.2 ± 26.80 |
| Dyspnea, CFB to C4D1 | 0.9 ± 27.96 | 0.8 ± 25.99 | 6.3 ± 27.96 |
| Dyspnea, CFB to C5D1 | 2.0 ± 30.02 | 1.3 ± 26.81 | 2.9 ± 25.42 |
| Dyspnea, CFB to C6D1 | -0.2 ± 27.63 | 2.1 ± 23.79 | 3.8 ± 26.94 |
| Dyspnea, CFB to C9D1 | 1.3 ± 29.03 | 4.3 ± 26.12 | 13.8 ± 28.89 |
| Dyspnea, CFB to C12D1 | 0.9 ± 27.93 | -4.5 ± 25.11 | 21.6 ± 28.73 |
| Dyspnea, CFB to C15D1 | -1.7 ± 20.16 | -6.1 ± 24.33 | 25.0 ± 38.83 |
| Dyspnea, CFB to C18D1 | 1.6 ± 24.07 | -7.8 ± 22.63 | 8.3 ± 16.67 |
| Dyspnea, CFB to C22D1 | 0.8 ± 25.26 | -3.0 ± 22.79 | 16.7 ± 23.57 |
| Dyspnea, CFB to C26D1 | 0 ± 34.36 | 10.4 ± 26.44 | 0 ± NA |
| Dyspnea, CFB to C30D1 | 0 ± 28.28 | 2.4 ± 20.52 | 33.3 ± NA |
| Dyspnea, CFB to C34D1 | -5.3 ± 33.82 | 0 ± 27.22 | 0 ± NA |
| Dyspnea, CFB to C38D1 | -10.3 ± 25.04 | 5.6 ± 25.09 | — |
| Dyspnea, CFB to C42D1 | -4.2 ± 11.79 | 16.7 ± 33.33 | 0 ± NA |
| Dyspnea, CFB to C46D1 | 6.7 ± 14.91 | 33.3 ± 0 | 0 ± NA |
| Dyspnea, CFB to C50D1 | 0 ± 23.57 | 0 ± NA | — |
| Dyspnea, CFB to C54D1 | -5.6 ± 25.09 | 0 ± 0 | — |
| Dyspnea, CFB to C58D1 | -16.7 ± 23.57 | 0 ± NA | — |
| Dyspnea, CFB to C62D1 | -33.3 ± 0 | 0 ± NA | — |
| Dyspnea, CFB to C66D1 | — | 33.3 ± NA | — |
| Dyspnea, CFB to EOT (~216 weeks) | 11.4 ± 30.74 | 11.6 ± 32.88 | 12.1 ± 30.74 |
| Dyspnea, CFB to SFU D30(~220 weeks) | 9.4 ± 33.29 | 8.5 ± 36.45 | 6.9 ± 29.45 |
| Dyspnea, CFB to SFU D90(~229 weeks) | -9.5 ± 27.51 | 33.3 ± 37.61 | 2.1 ± 33.26 |
| Insomnia, CFB to C2D1 | -3.3 ± 25.83 | -2.7 ± 30.24 | -1.0 ± 30.82 |
| Insomnia, CFB to C3D1 | -7.9 ± 25.33 | 0.2 ± 31.76 | 0.4 ± 30.72 |
| Insomnia, CFB to C4D1 | -6.6 ± 26.51 | -0.6 ± 30.29 | 0.5 ± 32.40 |
| Insomnia, CFB to C5D1 | -4.5 ± 28.81 | 0.3 ± 32.41 | 2.3 ± 30.12 |
| Insomnia, CFB to C6D1 | -4.3 ± 28.03 | -1.8 ± 30.16 | -1.3 ± 33.63 |
| Insomnia, CFB to C9D1 | -5.3 ± 25.70 | 1.2 ± 33.11 | -1.1 ± 20.86 |
| Insomnia, CFB to C12D1 | -0.9 ± 26.83 | 1.1 ± 33.88 | 3.9 ± 26.04 |
| Insomnia, CFB to C15D1 | -3.4 ± 23.93 | -5.1 ± 28.14 | 8.3 ± 23.57 |
| Insomnia, CFB to C18D1 | 2.3 ± 23.45 | 4.4 ± 31.24 | 8.3 ± 16.67 |
| Insomnia, CFB to C22D1 | 1.6 ± 21.02 | -4.5 ± 27.78 | 0 ± 0 |
| Insomnia, CFB to C26D1 | -2.9 ± 23.74 | -3.9 ± 30.92 | 0 ± NA |
| Insomnia, CFB to C30D1 | -3.8 ± 17.20 | 2.4 ± 33.24 | 33.3 ± NA |
| Insomnia, CFB to C34D1 | -3.5 ± 15.29 | 28.6 ± 35.63 | 0 ± NA |
| Insomnia, CFB to C38D1 | -2.6 ± 9.25 | 11.1 ± 34.43 | — |
| Insomnia, CFB to C42D1 | 4.2 ± 21.36 | 33.3 ± 27.22 | 0 ± NA |
| Insomnia, CFB to C46D1 | 6.7 ± 36.51 | 50.0 ± 23.57 | 0 ± NA |
| Insomnia, CFB to C50D1 | 6.7 ± 14.91 | 33.3 ± NA | — |
| Insomnia, CFB to C54D1 | 0 ± 21.08 | 33.3 ± 47.14 | — |
| Insomnia, CFB to C58D1 | -16.7 ± 23.57 | 33.3 ± NA | — |
| Insomnia, CFB to C62D1 | 0 ± 0 | 0 ± NA | — |
| Insomnia, CFB to C66D1 | — | 33.3 ± NA | — |
| Insomnia, CFB to EOT (~216 weeks) | 5.6 ± 31.44 | 6.5 ± 32.44 | 1.0 ± 35.76 |
| Insomnia, CFB to SFU D30(~220 weeks) | -5.3 ± 31.51 | 2.6 ± 29.00 | 1.4 ± 30.26 |
| Insomnia, CFB to SFU D90(~229 weeks) | 4.8 ± 31.64 | 1.4 ± 34.05 | -14.6 ± 34.36 |
| AL, CFB to C2D1 | 1.9 ± 28.68 | 1.9 ± 28.23 | 5.4 ± 25.79 |
| AL, CFB to C3D1 | -2.1 ± 28.42 | 3.1 ± 31.03 | 5.4 ± 27.64 |
| AL, CFB to C4D1 | -0.7 ± 26.84 | -0.2 ± 27.68 | 3.2 ± 32.25 |
| AL, CFB to C5D1 | 3.7 ± 29.02 | -0.8 ± 32.93 | 2.9 ± 27.66 |
| AL, CFB to C6D1 | 1.8 ± 27.90 | -1.8 ± 30.16 | -1.9 ± 25.92 |
| AL, CFB to C9D1 | -3.0 ± 26.42 | 3.5 ± 33.34 | 3.4 ± 22.44 |
| AL, CFB to C12D1 | 6.2 ± 28.84 | 3.4 ± 33.16 | 5.9 ± 21.20 |
| AL, CFB to C15D1 | 1.7 ± 29.57 | 3.4 ± 25.13 | 0 ± 17.82 |
| AL, CFB to C18D1 | -3.9 ± 31.88 | 0 ± 29.03 | 0 ± 27.22 |
| AL, CFB to C22D1 | 6.5 ± 29.08 | -3.0 ± 25.01 | 0 ± 0 |
| AL, CFB to C26D1 | -2.9 ± 34.20 | 2.0 ± 24.92 | 0 ± 0 |
| AL, CFB to C30D1 | -3.8 ± 33.10 | -2.4 ± 24.33 | -33.3 ± NA |
| AL, CFB to C34D1 | 0 ± 31.43 | -9.5 ± 37.09 | -33.3 ± NA |
| AL, CFB to C38D1 | -2.6 ± 34.59 | 11.1 ± 17.21 | — |
| AL, CFB to C42D1 | 0 ± 30.86 | 8.3 ± 16.67 | -33.3 ± NA |
| AL, CFB to C46D1 | -6.7 ± 36.51 | 0 ± 0 | -33.3 ± NA |
| AL, CFB to C50D1 | 0 ± 40.82 | 0 ± NA | — |
| AL, CFB to C54D1 | -16.7 ± 40.82 | 0 ± 0 | — |
| AL, CFB to C58D1 | -33.3 ± 47.14 | 0 ± NA | — |
| AL, CFB to C62D1 | 0 ± 0 | 0 ± NA | — |
| AL, CFB to C66D1 | — | 0 ± NA | — |
| AL, CFB to EOT (~216 weeks) | 12.1 ± 31.90 | 8.0 ± 34.78 | 9.0 ± 30.47 |
| AL, CFB to SFU D30(~220 weeks) | 5.3 ± 32.44 | 3.4 ± 23.93 | 0 ± 24.08 |
| AL, CFB to SFU D90(~229 weeks) | -7.1 ± 41.71 | 10.1 ± 29.19 | -4.2 ± 23.96 |
| Constipation, CFB to C2D1 | -0.9 ± 21.87 | -2.4 ± 25.34 | -1.3 ± 25.29 |
| Constipation, CFB to C3D1 | -0.3 ± 20.92 | -0.4 ± 26.69 | -1.4 ± 25.83 |
| Constipation, CFB to C4D1 | -0.7 ± 21.79 | -5.0 ± 27.44 | 1.8 ± 29.14 |
| Constipation, CFB to C5D1 | 0.8 ± 21.58 | -2.8 ± 25.01 | 0 ± 30.86 |
| Constipation, CFB to C6D1 | -2.0 ± 24.66 | -3.5 ± 26.11 | -4.5 ± 25.59 |
| Constipation, CFB to C9D1 | 0.7 ± 21.07 | -3.5 ± 30.87 | 2.3 ± 25.09 |
| Constipation, CFB to C12D1 | 0.4 ± 21.57 | -4.5 ± 28.67 | 9.8 ± 15.66 |
| Constipation, CFB to C15D1 | -0.6 ± 20.22 | -10.3 ± 28.77 | 4.2 ± 11.79 |
| Constipation, CFB to C18D1 | -1.6 ± 22.95 | -13.3 ± 27.12 | 8.3 ± 16.67 |
| Constipation, CFB to C22D1 | -3.3 ± 22.12 | -7.6 ± 22.84 | 0 ± 0 |
| Constipation, CFB to C26D1 | 1.0 ± 17.38 | -7.8 ± 27.71 | 0 ± NA |
| Constipation, CFB to C30D1 | -1.3 ± 19.96 | -4.8 ± 31.64 | 0 ± NA |
| Constipation, CFB to C34D1 | -1.8 ± 17.48 | 0 ± 27.22 | 0 ± NA |
| Constipation, CFB to C38D1 | -7.7 ± 14.62 | -5.6 ± 13.61 | — |
| Constipation, CFB to C42D1 | 0 ± 17.82 | 8.3 ± 31.91 | 0 ± NA |
| Constipation, CFB to C46D1 | -6.7 ± 14.91 | 33.3 ± 0 | 0 ± NA |
| Constipation, CFB to C50D1 | -6.7 ± 14.91 | 0 ± NA | — |
| Constipation, CFB to C54D1 | -5.6 ± 13.61 | 0 ± NA | — |
| Constipation, CFB to C58D1 | 16.7 ± 23.57 | 0 ± NA | — |
| Constipation, CFB to C62D1 | 0 ± 0 | 0 ± NA | — |
| Constipation, CFB to C66D1 | — | 33.3 ± NA | — |
| Constipation, CFB to EOT (~216 weeks) | 6.1 ± 25.09 | -4.3 ± 30.09 | 3.0 ± 27.67 |
| Constipation, CFB to SFU D30(~220 weeks) | 1.7 ± 28.56 | -8.5 ± 28.32 | -6.9 ± 27.77 |
| Constipation, CFB to SFU D90(~229 weeks) | 11.9 ± 28.06 | -8.7 ± 27.00 | -8.3 ± 22.77 |
| Diarrhea, CFB to C2D1 | 2.1 ± 18.05 | 3.5 ± 21.29 | 4.1 ± 18.31 |
| Diarrhea, CFB to C3D1 | 2.5 ± 17.18 | 4.3 ± 17.87 | 5.0 ± 19.53 |
| Diarrhea, CFB to C4D1 | 2.5 ± 17.06 | 3.7 ± 18.26 | 3.2 ± 14.77 |
| Diarrhea, CFB to C5D1 | 3.9 ± 17.08 | 2.1 ± 18.59 | 1.8 ± 17.16 |
| Diarrhea, CFB to C6D1 | 3.6 ± 16.56 | 2.9 ± 18.13 | 1.9 ± 15.36 |
| Diarrhea, CFB to C9D1 | 3.6 ± 18.80 | 2.4 ± 17.66 | 8.0 ± 21.19 |
| Diarrhea, CFB to C12D1 | 1.8 ± 18.90 | 3.4 ± 18.41 | 2.0 ± 14.29 |
| Diarrhea, CFB to C15D1 | -1.7 ± 14.54 | -2.6 ± 11.81 | 0 ± 0 |
| Diarrhea, CFB to C18D1 | 3.9 ± 14.92 | -6.7 ± 16.14 | 8.3 ± 16.67 |
| Diarrhea, CFB to C22D1 | -0.8 ± 13.92 | -6.1 ± 16.70 | 0 ± 0 |
| Diarrhea, CFB to C26D1 | 1.0 ± 15.32 | -5.9 ± 17.62 | 0 ± NA |
| Diarrhea, CFB to C30D1 | -2.6 ± 13.07 | -2.4 ± 15.82 | 0 ± NA |
| Diarrhea, CFB to C34D1 | 1.8 ± 17.48 | -4.8 ± 12.60 | 0 ± NA |
| Diarrhea, CFB to C38D1 | -2.6 ± 16.45 | 0 ± 21.08 | — |
| Diarrhea, CFB to C42D1 | 0 ± 0 | 8.3 ± 16.67 | 0 ± NA |
| Diarrhea, CFB to C46D1 | 0 ± 0 | 0 ± 0 | 0 ± NA |
| Diarrhea, CFB to C50D1 | 0 ± 0 | 0 ± NA | — |
| Diarrhea, CFB to C54D1 | 5.6 ± 13.61 | 0 ± 0 | — |
| Diarrhea, CFB to C58D1 | 0 ± 0 | 0 ± NA | — |
| Diarrhea, CFB to C62D1 | 16.7 ± 23.57 | 0 ± NA | — |
| Diarrhea, CFB to C66D1 | — | 0 ± NA | — |
| Diarrhea, CFB to EOT (~216 weeks) | 4.8 ± 22.20 | 2.9 ± 20.72 | 4.5 ± 18.25 |
| Diarrhea, CFB to SFU D30(~220 weeks) | 4.3 ± 21.87 | 7.7 ± 16.15 | 1.4 ± 15.48 |
| Diarrhea, CFB to SFU D90(~229 weeks) | -2.4 ± 20.52 | 2.9 ± 26.43 | -2.1 ± 8.33 |
| FD, CFB to C2D1 | -2.5 ± 23.44 | -1.7 ± 22.17 | 2.5 ± 20.51 |
| FD, CFB to C3D1 | 0.3 ± 24.31 | -1.6 ± 22.66 | 2.9 ± 20.17 |
| FD, CFB to C4D1 | -1.4 ± 22.68 | 0.2 ± 22.82 | 2.7 ± 24.52 |
| FD, CFB to C5D1 | 0.8 ± 23.04 | -0.5 ± 24.48 | -1.2 ± 21.99 |
| FD, CFB to C6D1 | 1.4 ± 21.61 | 1.5 ± 20.11 | -1.9 ± 16.72 |
| FD, CFB to C9D1 | 1.3 ± 22.07 | 5.1 ± 28.41 | -1.1 ± 18.86 |
| FD, CFB to C12D1 | -0.4 ± 24.19 | 0 ± 21.63 | -2.0 ± 14.29 |
| FD, CFB to C15D1 | 0 ± 24.98 | 2.6 ± 23.43 | 0 ± 0 |
| FD, CFB to C18D1 | -0.8 ± 17.04 | 1.1 ± 22.29 | 0 ± 0 |
| FD, CFB to C22D1 | 5.7 ± 26.77 | 3.0 ± 17.55 | 0 ± 0 |
| FD, CFB to C26D1 | 1.0 ± 23.90 | 2.0 ± 18.52 | 0 ± NA |
| FD, CFB to C30D1 | 3.8 ± 17.20 | 4.8 ± 25.68 | 0 ± NA |
| FD, CFB to C34D1 | -1.8 ± 17.48 | 9.5 ± 31.71 | 0 ± NA |
| FD, CFB to C38D1 | 0 ± 23.57 | 11.1 ± 34.43 | — |
| FD, CFB to C42D1 | 4.2 ± 45.21 | 8.3 ± 31.91 | 0 ± NA |
| FD, CFB to C46D1 | 0 ± 40.82 | -16.7 ± 23.57 | 0 ± NA |
| FD, CFB to C50D1 | -6.7 ± 36.51 | 0 ± NA | — |
| FD, CFB to C54D1 | 11.1 ± 34.43 | -16.7 ± 23.57 | — |
| FD, CFB to C58D1 | 0 ± 0 | -33.3 ± 0 | — |
| FD, CFB to C62D1 | 0 ± 0 | -33.3 ± NA | — |
| FD, CFB to C66D1 | — | 0 ± NA | — |
| FD, CFB to EOT (~216 weeks) | 5.8 ± 27.67 | 7.1 ± 26.64 | 5.5 ± 26.97 |
| FD, CFB to SFU D30(~220 weeks) | 1.7 ± 28.56 | 5.1 ± 23.62 | -4.2 ± 26.58 |
| FD, CFB to SFU D90(~229 weeks) | 0 ± 22.65 | 2.9 ± 26.43 | 8.3 ± 25.82 |
The QLQ-LC13 questionnaire comprises 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea and site-specific pain which includes pain in chest, pain in arm or shoulder and pain in other parts), and treatment-related side effects (sore mouth \[SM\], dysphagia, peripheral neuropathy \[PN\] and alopecia). Response options are 1 (Not at all) to 4 (Very much). Scores were averaged and transformed to 0 to 100. Higher scores represent increasing symptom levels. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Scores on Scale | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| Dyspnea, CFB to C2D1 | 1.9 ± 17.41 | 0.8 ± 17.57 | 4.2 ± 17.80 |
| Dyspnea, CFB to C3D1 | 3.5 ± 20.81 | 2.9 ± 18.54 | 2.3 ± 15.79 |
| Dyspnea, CFB to C4D1 | 3.1 ± 19.80 | 3.4 ± 18.11 | 5.8 ± 19.05 |
| Dyspnea, CFB to C5D1 | 5.8 ± 21.53 | 5.0 ± 17.79 | 6.7 ± 22.99 |
| Dyspnea, CFB to C6D1 | 5.4 ± 21.22 | 4.6 ± 17.63 | 4.3 ± 16.01 |
| Dyspnea, CFB to C9D1 | 6.2 ± 22.90 | 6.7 ± 17.00 | 9.1 ± 22.03 |
| Dyspnea, CFB to C12D1 | 6.1 ± 21.31 | 3.8 ± 17.48 | 17.6 ± 24.55 |
| Dyspnea, CFB to C15D1 | 7.3 ± 17.92 | -2.0 ± 17.08 | 23.6 ± 34.34 |
| Dyspnea, CFB to C18D1 | 5.0 ± 14.00 | -1.5 ± 16.18 | 22.2 ± 18.14 |
| Dyspnea, CFB to C22D1 | 6.5 ± 17.21 | -5.1 ± 20.21 | 11.1 ± 15.71 |
| Dyspnea, CFB to C26D1 | 8.7 ± 15.65 | -2.0 ± 21.24 | 0 ± NA |
| Dyspnea, CFB to C30D1 | 6.7 ± 15.71 | -0.8 ± 16.57 | 0 ± NA |
| Dyspnea, CFB to C34D1 | 8.3 ± 20.35 | 4.8 ± 14.14 | 0 ± NA |
| Dyspnea, CFB to C38D1 | 6.0 ± 20.09 | 3.7 ± 11.48 | — |
| Dyspnea, CFB to C42D1 | 2.8 ± 11.50 | 8.3 ± 18.98 | 22.2 ± NA |
| Dyspnea, CFB to C46D1 | 0 ± 15.71 | -5.6 ± 7.86 | 22.2 ± NA |
| Dyspnea, CFB to C50D1 | 3.7 ± 5.74 | -11.1 ± NA | — |
| Dyspnea, CFB to C54D1 | -1.9 ± 20.39 | -5.6 ± 7.86 | — |
| Dyspnea, CFB to C58D1 | 7.4 ± 6.42 | -11.1 ± NA | — |
| Dyspnea, CFB to C62D1 | -5.6 ± 7.86 | 0 ± NA | — |
| Dyspnea, CFB to C66D1 | — | 0 ± NA | — |
| Dyspnea, CFB to EOT (~216 weeks) | 14.3 ± 24.13 | 14.3 ± 26.58 | 9.7 ± 22.35 |
| Dyspnea, CFB to SFU D30 (~220 weeks) | 16.5 ± 21.95 | 13.9 ± 23.97 | 8.2 ± 23.98 |
| Dyspnea, CFB to SFU D90 (~229 weeks) | 9.5 ± 17.35 | 25.1 ± 21.25 | 4.2 ± 26.87 |
| Cough, CFB to C2D1 | -2.2 ± 23.06 | -1.7 ± 24.73 | -0.3 ± 23.57 |
| Cough, CFB to C3D1 | -2.2 ± 24.66 | -2.1 ± 26.13 | -3.6 ± 25.88 |
| Cough, CFB to C4D1 | 0.6 ± 26.76 | -0.9 ± 29.66 | -4.0 ± 26.92 |
| Cough, CFB to C5D1 | -2.5 ± 26.87 | -2.1 ± 27.67 | -4.3 ± 26.73 |
| Cough, CFB to C6D1 | 0.2 ± 27.76 | -4.8 ± 25.36 | -4.0 ± 29.84 |
| Cough, CFB to C9D1 | -0.7 ± 23.30 | -2.1 ± 29.97 | -1.1 ± 28.84 |
| Cough, CFB to C12D1 | -2.3 ± 25.40 | -7.5 ± 32.47 | 15.7 ± 37.49 |
| Cough, CFB to C15D1 | 0.6 ± 17.56 | -6.0 ± 28.48 | 16.7 ± 30.86 |
| Cough, CFB to C18D1 | 0.8 ± 21.99 | -13.3 ± 29.81 | -8.3 ± 16.67 |
| Cough, CFB to C22D1 | 0.8 ± 26.34 | -16.7 ± 19.92 | 0 ± 0 |
| Cough, CFB to C26D1 | -1.0 ± 26.07 | -7.8 ± 25.08 | 0 ± NA |
| Cough, CFB to C30D1 | -6.7 ± 27.22 | -9.5 ± 20.37 | -33.3 ± NA |
| Cough, CFB to C34D1 | -1.7 ± 20.16 | -4.8 ± 23.00 | -33.3 ± NA |
| Cough, CFB to C38D1 | -7.7 ± 27.74 | -5.6 ± 32.77 | — |
| Cough, CFB to C42D1 | -20.8 ± 24.80 | 16.7 ± 33.33 | 0 ± NA |
| Cough, CFB to C46D1 | -27.8 ± 38.97 | -16.7 ± 23.57 | -33.3 ± NA |
| Cough, CFB to C50D1 | -16.7 ± 45.95 | -33.3 ± NA | — |
| Cough, CFB to C54D1 | -33.3 ± 36.51 | 0 ± 0 | — |
| Cough, CFB to C58D1 | -22.2 ± 19.25 | -33.3 ± NA | — |
| Cough, CFB to C62D1 | -16.7 ± 23.57 | -33.3 ± NA | — |
| Cough, CFB to C66D1 | — | 0 ± NA | — |
| Cough, CFB to EOT(~216 weeks) | 2.4 ± 28.55 | 2.8 ± 32.18 | 2.1 ± 28.79 |
| Cough, CFB to SFU D30 (~220 weeks) | 2.9 ± 33.70 | 3.3 ± 32.73 | -1.4 ± 23.52 |
| Cough, CFB to SFU D90(~229 weeks) | -4.8 ± 22.10 | 7.2 ± 31.71 | 0 ± 21.08 |
| Hemoptysis, CFB to C2D1 | -0.7 ± 10.93 | -2.5 ± 11.08 | 0.3 ± 10.10 |
| Hemoptysis, CFB to C3D1 | -1.3 ± 10.64 | -1.3 ± 12.08 | 0.4 ± 14.16 |
| Hemoptysis, CFB to C4D1 | -1.4 ± 13.82 | -1.9 ± 10.87 | 0 ± 12.97 |
| Hemoptysis, CFB to C5D1 | -2.0 ± 13.60 | -1.3 ± 11.38 | 0 ± 12.95 |
| Hemoptysis, CFB to C6D1 | -1.9 ± 15.00 | -1.8 ± 8.81 | -0.7 ± 10.63 |
| Hemoptysis, CFB to C9D1 | -2.6 ± 13.43 | -0.8 ± 10.51 | 0 ± 8.91 |
| Hemoptysis, CFB to C12D1 | -1.4 ± 16.37 | -1.7 ± 11.55 | 2.0 ± 8.08 |
| Hemoptysis, CFB to C15D1 | -0.6 ± 10.12 | 1.7 ± 10.68 | 0 ± 17.82 |
| Hemoptysis, CFB to C18D1 | 0 ± 7.55 | -2.2 ± 8.46 | 0 ± 0 |
| Hemoptysis, CFB to C22D1 | 3.3 ± 14.54 | -3.0 ± 9.81 | 0 ± 0 |
| Hemoptysis, CFB to C26D1 | -2.1 ± 8.20 | -2.0 ± 14.29 | 0 ± NA |
| Hemoptysis, CFB to C30D1 | -1.3 ± 6.67 | -4.8 ± 12.10 | 0 ± NA |
| Hemoptysis, CFB to C34D1 | 0 ± 0 | -4.8 ± 12.60 | 0 ± NA |
| Hemoptysis, CFB to C38D1 | -2.6 ± 9.25 | -5.6 ± 13.61 | — |
| Hemoptysis, CFB to C42D1 | 0 ± 0 | -8.3 ± 16.67 | 0 ± NA |
| Hemoptysis, CFB to C46D1 | -5.6 ± 13.61 | -16.7 ± 23.57 | 0 ± NA |
| Hemoptysis, CFB to C50D1 | -5.6 ± 13.61 | 0 ± NA | — |
| Hemoptysis, CFB to C54D1 | -5.6 ± 13.61 | -16.7 ± 23.57 | — |
| Hemoptysis, CFB to C58D1 | 0 ± 0 | 0 ± NA | — |
| Hemoptysis, CFB to C62D1 | 0 ± 0 | 0 ± NA | — |
| Haemoptysis, CFB to C66D1 | — | 0 ± NA | — |
| Hemoptysis, CFB to EOT(~216 weeks) | 2.7 ± 12.76 | 1.3 ± 15.08 | 1.0 ± 11.74 |
| Hemoptysis, CFB to SFU D30 | -1.0 ± 12.75 | 2.5 ± 8.89 | -1.4 ± 6.95 |
| Hemoptysis, CFB to SFU D90(~229 weeks) | 0 ± 13.07 | 2.9 ± 13.90 | 2.1 ± 8.33 |
| SM, CFB to C2D1 | 5.6 ± 21.37 | 5.2 ± 24.18 | 3.0 ± 19.69 |
| SM, CFB to C3D1 | 7.7 ± 22.06 | 7.5 ± 26.12 | 3.2 ± 19.78 |
| SM, CFB to C4D1 | 5.3 ± 18.97 | 6.0 ± 21.25 | 2.5 ± 21.17 |
| SM, CFB to C5D1 | 6.0 ± 19.40 | 6.3 ± 24.66 | 3.1 ± 20.75 |
| SM, CFB to C6D1 | 5.3 ± 18.12 | 2.7 ± 17.49 | 2.7 ± 21.12 |
| SM, CFB to C9D1 | 4.0 ± 18.48 | 2.5 ± 18.84 | 6.9 ± 22.50 |
| SM, CFB to C12D1 | 0.5 ± 13.21 | 2.3 ± 22.39 | 2.0 ± 18.52 |
| SM, CFB to C15D1 | 2.4 ± 15.52 | -1.7 ± 18.65 | 12.5 ± 35.36 |
| SM, CFB to C18D1 | -0.8 ± 9.21 | -1.1 ± 16.34 | 0 ± 0 |
| SM, CFB to C22D1 | 0 ± 7.45 | 3.0 ± 14.21 | 0 ± 0 |
| SM, CFB to C26D1 | 2.1 ± 14.51 | 2.0 ± 14.29 | 0 ± 0 |
| SM, CFB to C30D1 | 2.7 ± 13.33 | 2.4 ± 8.91 | 0 ± NA |
| SM, CFB to C34D1 | 1.7 ± 13.13 | 4.8 ± 12.60 | 0 ± NA |
| SM, CFB to C38D1 | 2.6 ± 9.25 | 0 ± 0 | — |
| SM, CFB to C42D1 | 0 ± 0 | 16.7 ± 19.25 | 0 ± NA |
| SM, CFB to C46D1 | 5.6 ± 13.61 | 16.7 ± 23.57 | 0 ± NA |
| SM, CFB to C50D1 | 0 ± 0 | 0 ± NA | — |
| SM, CFB to C54D1 | 0 ± 0 | 0 ± 0 | — |
| SM, CFB to C58D1 | 0 ± 0 | 0 ± NA | — |
| SM, CFB to C62D1 | 0 ± 0 | 0 ± NA | — |
| SM, CFB to C66D1 | — | 33.3 ± NA | — |
| SM, CFB to EOT(~216 weeks) | 3.3 ± 15.47 | 8.3 ± 25.18 | 1.0 ± 17.65 |
| SM, CFB to SFU D30 (~220 weeks) | 2.9 ± 21.95 | 1.7 ± 15.00 | 1.4 ± 15.82 |
| SM, CFB to SFU D90 (~229 weeks) | 2.4 ± 8.91 | 1.4 ± 21.27 | 8.3 ± 19.25 |
| Dysphagia, CFB to C2D1 | 1.0 ± 17.62 | 2.2 ± 15.34 | 2.0 ± 18.94 |
| Dysphagia, CFB to C3D1 | 0.7 ± 18.33 | 4.0 ± 16.17 | 5.6 ± 23.04 |
| Dysphagia, CFB to C4D1 | 0 ± 17.01 | 1.9 ± 16.17 | 4.5 ± 20.84 |
| Dysphagia, CFB to C5D1 | 2.0 ± 16.14 | 2.1 ± 19.95 | 3.1 ± 16.21 |
| Dysphagia, CFB to C6D1 | 0.7 ± 15.84 | 0.3 ± 14.56 | 2.7 ± 17.61 |
| Dysphagia, CFB to C9D1 | 1.5 ± 16.41 | 1.6 ± 13.85 | 1.1 ± 14.04 |
| Dysphagia, CFB to C12D1 | -2.8 ± 13.51 | 5.2 ± 21.45 | 3.9 ± 11.07 |
| Dysphagia, CFB to C15D1 | -1.2 ± 12.77 | -0.9 ± 5.34 | 4.2 ± 11.79 |
| Dysphagia, CFB to C18D1 | 0.8 ± 11.91 | 0 ± 8.75 | 0 ± 0 |
| Dysphagia, CFB to C22D1 | -1.6 ± 12.80 | -3.0 ± 9.81 | 0 ± 0 |
| Dysphagia, CFB to C26D1 | -1.0 ± 13.35 | 0 ± 11.79 | 0 ± NA |
| Dysphagia, CFB to C30D1 | -1.3 ± 11.71 | 2.4 ± 8.91 | 0 ± NA |
| Dysphagia, CFB to C34D1 | -1.7 ± 7.45 | 14.3 ± 26.23 | 0 ± NA |
| Dysphagia, CFB to C38D1 | -2.6 ± 9.25 | 0 ± 0 | — |
| Dysphagia, CFB to C42D1 | 4.2 ± 11.79 | 0 ± 0 | 0 ± NA |
| Dysphagia, CFB to C46D1 | 0 ± 0 | 0 ± 0 | 0 ± NA |
| Dysphagia, CFB to C50D1 | 0 ± 0 | 0 ± NA | — |
| Dysphagia, CFB to C54D1 | -5.6 ± 13.61 | 0 ± 0 | — |
| Dysphagia, CFB to C58D1 | -11.1 ± 19.25 | 0 ± NA | — |
| Dysphagia, CFB to C62D1 | -16.7 ± 23.57 | 0 ± NA | — |
| Dysphagia, CFB to C66D1 | — | 33.3 ± NA | — |
| Dysphagia, CFB to EOT(~216 weeks) | 5.4 ± 19.79 | 8.3 ± 20.33 | 5.6 ± 18.23 |
| Dysphagia, CFB to SFU D30 (~220 weeks) | 1.9 ± 22.78 | 0.8 ± 14.10 | 2.9 ± 24.44 |
| Dysphagia, CFB to SFU D90 (~229 weeks) | 7.1 ± 14.19 | 8.7 ± 20.64 | 4.2 ± 11.39 |
| PN, CFB to C2D1 | 2.7 ± 19.38 | -1.0 ± 22.14 | 2.7 ± 21.12 |
| PN, CFB to C3D1 | 3.4 ± 24.46 | 1.0 ± 25.01 | 4.8 ± 22.64 |
| PN, CFB to C4D1 | 5.3 ± 23.94 | 3.4 ± 26.01 | 8.5 ± 22.73 |
| PN, CFB to C5D1 | 10.6 ± 29.11 | 9.1 ± 27.97 | 1.2 ± 20.44 |
| PN, CFB to C6D1 | 10.0 ± 24.71 | 6.9 ± 29.17 | 6.0 ± 25.81 |
| PN, CFB to C9D1 | 9.3 ± 27.83 | 12.8 ± 29.61 | 9.5 ± 23.76 |
| PN, CFB to C12D1 | 11.9 ± 26.64 | 5.7 ± 21.75 | 9.8 ± 15.66 |
| PN, CFB to C15D1 | 7.9 ± 27.19 | 7.7 ± 30.07 | 4.2 ± 21.36 |
| PN, CFB to C18D1 | 14.2 ± 30.09 | 5.6 ± 30.43 | 16.7 ± 19.25 |
| PN, CFB to C22D1 | 6.5 ± 23.83 | 9.1 ± 27.57 | 16.7 ± 23.57 |
| PN, CFB to C26D1 | 1.0 ± 29.92 | 3.9 ± 30.92 | 0 ± NA |
| PN, CFB to C30D1 | 10.7 ± 24.94 | 0 ± 18.49 | 0 ± NA |
| PN, CFB to C34D1 | -5.0 ± 27.09 | 14.3 ± 17.82 | 0 ± NA |
| PN, CFB to C38D1 | 0 ± 33.33 | 0 ± 21.08 | — |
| PN, CFB to C42D1 | -4.2 ± 21.36 | 16.7 ± 19.25 | 33.3 ± NA |
| PN, CFB to C46D1 | -5.6 ± 25.09 | 0 ± 0 | 0 ± NA |
| PN, CFB to C50D1 | 5.6 ± 25.09 | 0 ± NA | — |
| PN, CFB to C54D1 | -11.1 ± 40.37 | 0 ± 0 | — |
| PN, CFB to C58D1 | -22.2 ± 50.92 | 0 ± NA | — |
| PN, CFB to C62D1 | -50.0 ± 23.57 | 0 ± NA | — |
| PN, CFB to C66D1 | — | 0 ± NA | — |
| PN, CFB to EOT(~216 weeks) | 11.4 ± 27.52 | 11.1 ± 28.44 | 8.3 ± 28.48 |
| PN, CFB to SFU D30 (~220 weeks) | 6.7 ± 25.31 | 11.7 ± 24.52 | 13.0 ± 24.08 |
| PN, CFB to SFU D90 (~229 weeks) | 14.3 ± 38.60 | 10.1 ± 25.49 | 6.3 ± 27.81 |
| Alopecia, CFB to C2D1 | 41.3 ± 40.53 | 42.5 ± 43.95 | 42.4 ± 42.54 |
| Alopecia, CFB to C3D1 | 41.4 ± 36.95 | 40.6 ± 40.05 | 38.9 ± 43.24 |
| Alopecia, CFB to C4D1 | 34.5 ± 35.69 | 36.8 ± 41.51 | 35.8 ± 40.75 |
| Alopecia, CFB to C5D1 | 37.8 ± 35.23 | 36.7 ± 37.38 | 34.0 ± 39.65 |
| Alopecia, CFB to C6D1 | 38.9 ± 35.93 | 37.2 ± 40.14 | 36.7 ± 38.83 |
| Alopecia, CFB to C9D1 | 23.8 ± 37.61 | 30.0 ± 44.60 | 40.2 ± 43.08 |
| Alopecia, CFB to C12D1 | 19.2 ± 35.93 | 20.1 ± 37.95 | 41.2 ± 41.72 |
| Alopecia, CFB to C15D1 | 9.7 ± 33.13 | 5.1 ± 22.35 | 37.5 ± 45.21 |
| Alopecia, CFB to C18D1 | 0.8 ± 25.58 | 5.6 ± 27.80 | 58.3 ± 50.00 |
| Alopecia, CFB to C22D1 | 7.3 ± 32.07 | 12.1 ± 28.26 | 16.7 ± 23.57 |
| Alopecia, CFB to C26D1 | -4.2 ± 22.00 | 2.0 ± 21.96 | 0 ± NA |
| Alopecia, CFB to C30D1 | -2.7 ± 21.34 | 2.4 ± 24.33 | 0 ± NA |
| Alopecia, CFB to C34D1 | -1.7 ± 17.01 | 4.8 ± 12.60 | 0 ± NA |
| Alopecia, CFB to C38D1 | 0 ± 19.25 | 5.6 ± 25.09 | — |
| Alopecia, CFB to C42D1 | -4.2 ± 11.79 | -8.3 ± 16.67 | 100.0 ± NA |
| Alopecia, CFB to C46D1 | -5.6 ± 13.61 | -16.7 ± 23.57 | 0 ± NA |
| Alopecia, CFB to C50D1 | 0 ± 21.08 | 0 ± NA | — |
| Alopecia, CFB to C54D1 | 5.6 ± 13.61 | -16.7 ± 23.57 | — |
| Alopecia, CFB to C58D1 | 0 ± 0 | 0 ± NA | — |
| Alopecia, CFB to C62D1 | 0 ± 0 | 0 ± NA | — |
| Alopecia, CFB to C66D1 | — | 0 ± NA | — |
| Alopecia, CFB to EOT (~216 weeks) | 20.5 ± 38.55 | 21.7 ± 41.59 | 23.4 ± 39.25 |
| Alopecia, CFB to SFU D30 (~220 weeks) | 12.4 ± 33.42 | 7.5 ± 26.67 | 13.0 ± 32.94 |
| Alopecia, CFB to SFU D90 (~229 weeks) | 9.5 ± 42.22 | 5.8 ± 39.76 | 4.2 ± 26.87 |
| Pain in Chest, CFB to C2D1 | -2.3 ± 22.40 | 0 ± 21.91 | 2.4 ± 19.88 |
| Pain in Chest, CFB to C3D1 | -2.7 ± 18.40 | -1.0 ± 21.63 | 4.0 ± 20.43 |
| Pain in Chest, CFB to C4D1 | -1.8 ± 19.33 | -1.9 ± 21.16 | -1.0 ± 20.23 |
| Pain in Chest, CFB to C5D1 | -0.9 ± 21.63 | -2.6 ± 19.45 | -1.3 ± 23.54 |
| Pain in Chest, CFB to C6D1 | -0.7 ± 24.07 | 2.4 ± 19.44 | 0 ± 22.57 |
| Pain in Chest, CFB to C9D1 | 2.6 ± 20.74 | 2.9 ± 23.69 | 4.6 ± 19.36 |
| Pain in Chest, CFB to C12D1 | -0.5 ± 20.06 | 2.9 ± 25.20 | 11.8 ± 20.21 |
| Pain in Chest, CFB to C15D1 | 1.2 ± 14.29 | 0.9 ± 17.91 | 4.2 ± 11.79 |
| Pain in Chest, CFB to C18D1 | -3.3 ± 18.18 | 1.1 ± 16.34 | 0 ± 0 |
| Pain in Chest, CFB to C22D1 | 4.1 ± 19.99 | -6.1 ± 19.62 | 0 ± 0 |
| Pain in Chest, CFB to C26D1 | 0 ± 18.93 | -3.9 ± 23.22 | 0 ± NA |
| Pain in Chest, CFB to C30D1 | -1.3 ± 17.95 | -4.8 ± 25.68 | 0 ± NA |
| Pain in Chest, CFB to C34D1 | -1.7 ± 20.16 | 0 ± 19.25 | 0 ± NA |
| Pain in Chest, CFB to C38D1 | -5.1 ± 12.52 | -5.6 ± 38.97 | — |
| Pain in Chest, CFB to C42D1 | -4.2 ± 21.36 | 0 ± 0 | 0 ± NA |
| Pain in Chest, CFB to C46D1 | -5.6 ± 13.61 | 0 ± 0 | 0 ± NA |
| Pain in Chest, CFB to C50D1 | 0 ± 0 | 0 ± NA | — |
| Pain in Chest, CFB to C54D1 | -11.1 ± 17.21 | 0 ± 0 | — |
| Pain in Chest, CFB to C58D1 | -11.1 ± 19.25 | 0 ± NA | — |
| Pain in Chest, CFB to C62D1 | -16.7 ± 23.57 | 0 ± NA | — |
| Pain in Chest, CFB to C66D1 | — | 0 ± NA | — |
| Pain in Chest, CFB to EOT (~216 weeks) | 7.5 ± 26.09 | 5.3 ± 23.60 | 2.1 ± 24.59 |
| Pain in Chest, CFB to SFU D30 (~220 weeks) | 3.8 ± 21.04 | 6.7 ± 21.62 | 12.1 ± 28.26 |
| Pain in Chest, CFB to SFU D90 (~229 weeks) | -7.1 ± 14.19 | 8.7 ± 20.64 | -4.2 ± 31.91 |
| Pain in Arm or Shoulder, CFB to C2D1 | 1.0 ± 22.01 | -1.7 ± 21.33 | -0.3 ± 20.58 |
| Pain in Arm or Shoulder, CFB to C3D1 | -0.4 ± 22.19 | -3.1 ± 24.45 | 0 ± 22.69 |
| Pain in Arm or Shoulder, CFB to C4D1 | -0.8 ± 22.63 | 0 ± 23.65 | 0 ± 20.25 |
| Pain in Arm or Shoulder, CFB to C5D1 | 2.9 ± 24.79 | -1.8 ± 25.99 | -0.6 ± 24.01 |
| Pain in Arm or Shoulder, CFB to C6D1 | 1.0 ± 24.48 | -3.3 ± 22.45 | 2.0 ± 23.97 |
| Pain in Arm or Shoulder, CFB to C9D1 | 5.5 ± 26.88 | 0.4 ± 26.08 | -1.1 ± 20.86 |
| Pain in Arm or Shoulder, CFB to C12D1 | 6.6 ± 24.31 | 2.3 ± 24.07 | 3.9 ± 23.22 |
| Pain in Arm or Shoulder, CFB to C15D1 | 7.3 ± 19.97 | 2.6 ± 24.64 | -4.2 ± 11.79 |
| Pain in Arm or Shoulder, CFB to C18D1 | 5.0 ± 20.74 | 4.4 ± 24.34 | -8.3 ± 16.67 |
| Pain in Arm or Shoulder, CFB to C22D1 | 6.5 ± 21.37 | 6.1 ± 16.70 | 0 ± 0 |
| Pain in Arm or Shoulder, CFB to C26D1 | 6.3 ± 21.48 | 0 ± 20.41 | 0 ± NA |
| Pain in Arm or Shoulder, CFB to C30D1 | 13.3 ± 21.52 | -4.8 ± 22.10 | 0 ± NA |
| Pain in Arm or Shoulder, CFB to C34D1 | 13.3 ± 19.94 | 0 ± 27.22 | 0 ± NA |
| Pain in Arm or Shoulder, CFB to C38D1 | 2.6 ± 21.35 | -11.1 ± 50.18 | — |
| Pain in Arm or Shoulder, CFB to C42D1 | 4.2 ± 11.79 | -8.3 ± 16.67 | 0 ± NA |
| Pain in Arm or Shoulder, CFB to C46D1 | 5.6 ± 13.61 | -16.7 ± 23.57 | 33.3 ± NA |
| Pain in Arm or Shoulder, CFB to C50D1 | 5.6 ± 25.09 | -33.3 ± NA | — |
| Pain in Arm or Shoulder, CFB to C54D1 | 0 ± 29.81 | -33.3 ± 0 | — |
| Pain in Arm or Shoulder, CFB to C58D1 | 0 ± 33.33 | -33.3 ± NA | — |
| Pain in Arm or Shoulder, CFB to C62D1 | -16.7 ± 23.57 | -33.3 ± NA | — |
| Pain in Arm or Shoulder, CFB to C66D1 | — | -33.3 ± NA | — |
| Pain in Arm or Shoulder, CFB to EOT (~216 weeks) | 6.8 ± 27.27 | 6.6 ± 25.20 | -2.6 ± 23.23 |
| Pain in Arm or Shoulder, CFB to SFU D30 (~220 weeks) | 7.6 ± 33.42 | 6.7 ± 26.37 | 5.8 ± 27.80 |
| Pain in Arm or Shoulder, CFB to SFU D90 (~229 weeks) | -7.1 ± 35.03 | 0 ± 33.33 | 10.4 ± 29.11 |
| Pain in Other Parts, CFB to C2D1 | 0.2 ± 28.09 | -0.3 ± 25.73 | 2.4 ± 25.31 |
| Pain in Other Parts, CFB to C3D1 | 0.5 ± 28.04 | -3.3 ± 27.61 | 1.2 ± 30.37 |
| Pain in Other Parts, CFB to C4D1 | -1.6 ± 26.35 | -1.7 ± 29.37 | -1.0 ± 29.57 |
| Pain in Other Parts, CFB to C5D1 | 2.5 ± 30.53 | -0.3 ± 30.43 | -1.2 ± 30.35 |
| Pain in Other Parts, CFB to C6D1 | 1.5 ± 29.39 | 0.3 ± 31.77 | 4.0 ± 28.28 |
| Pain in Other Parts, CFB to C9D1 | 5.5 ± 29.09 | -2.1 ± 30.16 | 2.3 ± 26.62 |
| Pain in Other Parts, CFB to C12D1 | 2.8 ± 25.04 | -1.7 ± 27.52 | 5.9 ± 24.25 |
| Pain in Other Parts, CFB to C15D1 | -1.8 ± 23.50 | 1.7 ± 27.52 | 4.2 ± 21.36 |
| Pain in Other Parts, CFB to C18D1 | 2.5 ± 15.81 | -3.3 ± 33.16 | 8.3 ± 16.67 |
| Pain in Other Parts, CFB to C22D1 | 2.4 ± 18.84 | -10.6 ± 23.87 | 16.7 ± 23.57 |
| Pain in Other Parts, CFB to C26D1 | 5.4 ± 31.15 | -15.7 ± 37.49 | 0 ± NA |
| Pain in Other Parts, CFB to C30D1 | 2.7 ± 28.74 | -4.8 ± 28.81 | 0 ± NA |
| Pain in Other Parts, CFB to C34D1 | 1.7 ± 17.01 | -14.3 ± 17.82 | 0 ± NA |
| Pain in Other Parts, CFB to C38D1 | 7.7 ± 27.74 | -11.1 ± 34.43 | — |
| Pain in Other Parts, CFB to C42D1 | -4.2 ± 21.36 | -8.3 ± 16.67 | 0 ± NA |
| Pain in Other Parts, CFB to C46D1 | 0 ± 21.08 | -16.7 ± 23.57 | 33.3 ± NA |
| Pain in Other Parts, CFB to C50D1 | 0 ± 21.08 | 0 ± NA | — |
| Pain in Other Parts, CFB to C54D1 | -5.6 ± 25.09 | -33.3 ± 0 | — |
| Pain in Other Parts, CFB to C58D1 | 11.1 ± 19.25 | -33.3 ± NA | — |
| Pain in Other Parts, CFB to C62D1 | 16.7 ± 23.57 | -33.3 ± NA | — |
| Pain in Other Parts, CFB to C66D1 | — | 0 ± NA | — |
| Pain in Other Parts, CFB to EOT (~216 weeks) | 5.4 ± 31.18 | 6.2 ± 32.75 | 6.7 ± 33.95 |
| Pain in Other Parts, CFB to SFU D30(~220 weeks) | 2.9 ± 29.56 | 1.7 ± 31.48 | 8.7 ± 27.00 |
| Pain in Other Parts, CFB to SFU D90 (~229 weeks) | 4.8 ± 25.68 | 4.3 ± 32.26 | 8.3 ± 25.82 |
ECGs were recorded after the participants were in a supine or semi-recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes. ECG findings are summarized as clinically significant change from baseline worst case hierarchy: Yes \> No \> Not Applicable (NA).
| Participants | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| No | 20 | 16 | 15 |
| Yes | 8 | 3 | 3 |
| NA | 0 | 0 | 0 |
A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Results for this outcome have not been posted.
A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
Results for this outcome have not been posted.
Number of participants using concomitant medications will be presented.
Results for this outcome have not been posted.
Blood samples will be collected for the analysis of hematology parameters.
Results for this outcome have not been posted.
Blood samples will be collected for the analysis of Clinical Chemistry parameters.
Results for this outcome have not been posted.
Blood samples will be collected for the analysis of thyroid function
Results for this outcome have not been posted.
Urine samples will be collected to analyze urine specific gravity.
Results for this outcome have not been posted.
Vital signs will be assessed
Results for this outcome have not been posted.
Vital signs will be assessed and presented
Results for this outcome have not been posted.
Performance status will be assessed using the ECOG performance status scale.
Results for this outcome have not been posted.
Number of participants with abnormal physical examinations will be presented
No measurements were reported for this outcome.
Collected over All-cause mortality, serious adverse events (SAEs) and non-SAEs were collected up to approximately 234 weeks. Safety data collection is still ongoing, and additional results will be provided within a year of study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cobolimab + Dostarlimab + Docetaxel (Arm A) | 227/305 (74.4%) | 102/302 (33.8%) | 285/302 (94.4%) |
| Dostarlimab + Docetaxel (Arm B) | 236/301 (78.4%) | 126/295 (42.7%) | 276/295 (93.6%) |
| Docetaxel (Arm C) | 116/152 (76.3%) | 52/144 (36.1%) | 136/144 (94.4%) |
| Event | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| PneumoniaInfections and infestations | 19/302 | 24/295 | 12/144 |
| Febrile neutropeniaBlood and lymphatic system disorders | 9/302 | 15/295 | 2/144 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/302 | 3/295 | 4/144 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 6/302 | 6/295 | 1/144 |
| NeutropeniaBlood and lymphatic system disorders | 4/302 | 5/295 | 1/144 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/302 | 5/295 | 1/144 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 5/302 | 2/295 | 0/144 |
| AnaemiaBlood and lymphatic system disorders | 2/302 | 1/295 | 2/144 |
| Lower respiratory tract infectionInfections and infestations | 0/302 | 2/295 | 2/144 |
| Respiratory tract infectionInfections and infestations | 4/302 | 2/295 | 2/144 |
| Event | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 105/302 | 93/295 | 41/144 |
| NeutropeniaBlood and lymphatic system disorders | 95/302 | 77/295 | 38/144 |
| FatigueGeneral disorders | 89/302 | 88/295 | 40/144 |
| DiarrhoeaGastrointestinal disorders | 87/302 | 87/295 | 37/144 |
| AlopeciaSkin and subcutaneous tissue disorders | 78/302 | 69/295 | 40/144 |
| AstheniaGeneral disorders | 70/302 | 79/295 | 36/144 |
| NauseaGastrointestinal disorders | 74/302 | 68/295 | 30/144 |
| Decreased appetiteMetabolism and nutrition disorders | 61/302 | 69/295 | 27/144 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 52/302 | 51/295 | 27/144 |
| Neuropathy peripheralNervous system disorders | 35/302 | 29/295 | 24/144 |
| Age, Continuous(YEARS) | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 8.86 | 64.3 ± 9.85 | 64.0 ± 9.45 | 64.0 ± 9.37 |
| Sex: Female, Male(Participants) | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| Female | 98 | 100 | 47 | 245 |
| Male | 207 | 201 | 105 | 513 |
| Race/Ethnicity, Customized(Participants) | Cobolimab + Dostarlimab + Docetaxel (Arm A) | Dostarlimab + Docetaxel (Arm B) | Docetaxel (Arm C) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 7 | 5 | 4 | 16 |
| Asian | 37 | 44 | 24 | 105 |
| Black or African American | 2 | 8 | 1 | 11 |
| White | 245 | 224 | 119 | 588 |
| Mixed Race | 0 | 1 | 0 | 1 |
| Unknown | 3 | 5 | 2 | 10 |
| Not Reported | 11 | 14 | 2 | 27 |
Showing the first 100 of 163 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Dec 2020 to primary completion in Jun 2025, 53 months.
Results were first posted in Jul 2026, 1 year after primary completion.
Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's 53 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cobolimab · Dostarlimab
Carcinoma, Non-Small-Cell Lung →